The Effect of Losartan on Emotional Processing in Healthy Volunteers

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-06-01

Study Completion Date

2017-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This experimental medicine study explores whether a single dose of losartan (50mg) versus placebo affects the processing of positive and negative stimuli, using fMRI.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study to Investigate the Effects of GW876008 on Brain Activation During Emotional Processing in Healthy Subjects.

NCT00424697

Healthy Subjects

COMPLETED PHASE1

Self-regulation of Prefrontal Cortex During Emotional Cognitive Control

NCT04543500

Healthy Volunteers Cognitive Function

COMPLETED NA

Single-dose Novel Selective alpha2c Antagonist Pharmaco-MRI Study in Healthy Volunteers

NCT03440021

Healthy Volunteer

COMPLETED PHASE1

Neurofeedback as a Treatment Tool for Depression

NCT01544205

Unipolar Depression

COMPLETED NA

Expectation Effects on Emotional Processing

NCT07031804

Expectation Effects on Emotional Processing

NOT_YET_RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Losartan has been shown to accelerate fear extinction in animals and to prevent the development of anxiety disorders in humans, emphasising its potential to possibly enhance exposure therapy in humans. This study explores the basic effects of losartan on emotional processing, to identify neural mechanisms by which the drug might have synergistic effects on psychological treatment in humans.

In a double-blind between-groups design, 30 healthy volunteers will be randomised to a group receiving a single dose of losartan (50mg) versus placebo, and this study will measure the effects of probing renin-angiotensin function on emotional information processing, using functional magnet resonance imaging (fMRI). Such knowledge will ultimately be essential for the development of more effective pharmaco-psychological treatment approaches for anxiety disorders.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy Volunteers

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

This is a double-blind, placebo-controlled experimental medicine study, where healthy volunteers are randomised to receiving either a single dose of losartan (50mg) or matching placebo.

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

DOUBLE

Participants Investigators

Study medication and placebo are over-encapsulated to look identical, and both the participants and investigators in direct contact with partiicpants are blind to group allocation.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Losartan

single dose of 50mg losartan, tablet, over-encapsulated, to be taken orally

Group Type EXPERIMENTAL

Losartan

Intervention Type DRUG

blood pressure medication

Placebo

single dose of placebo (main ingredient microcrystalline cellulose), tablet, over-encapsulated, to be taken orally

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type OTHER

non-active sham intervention

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Losartan

blood pressure medication

Intervention Type DRUG

Placebo

non-active sham intervention

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Losartan Potassium

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* willing and able to provide informed consent
* male or Female, aged 18-50
* body mass index (BMI) of 18-30 kg/m2
* fluent English skills
* non- or light-smoker (\< 5 cigarettes a day)

Exclusion Criteria

* Female participant who is pregnant or breast-feeding
* central nervous system (CNS) active medication during the last 6 weeks
* Current blood pressure/other heart medication (esp. aliskiren or beta blockers)
* Intravascular fluid depletion
* Past or present DSM-IV (Diagnostic and Statistical Manual of Mental Disorders) axis-I diagnosis
* Alcohol or substance abuse
* First-degree family member with a history of a severe psychiatric disease
* Impaired liver or kidney function
* Lifetime history of epilepsy or other neurological disease, systemic infection, or clinically significant hepatic, cardiac, obstructive respiratory, renal, cerebrovascular, metabolic, endocrine or pulmonary disease or disorder which, in the opinion of the investigator, may either put the participants at risk because of participation in the study, or may influence the result of the study, or the participant's ability to participate in the study.
* Insufficient English skills
* participated in another study involving certain medication during last 6 weeks
* Contraindication to magnet resonance imaging (MRI) scanning (e.g. pacemaker)

Minimum Eligible Age

18 Years

Maximum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes